Literature DB >> 11021841

p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19.

W Hartmann1, A Waha, A Koch, C G Goodyer, S Albrecht, D von Schweinitz, T Pietsch.   

Abstract

Hepatoblastomas (HBs), representing malignant liver tumors of childhood, show frequent loss of heterozygosity (LOH) in the chromosomal region 11p15.5. This loss is of maternal origin suggesting the presence of a monoallelically expressed tumor suppressor gene in this region. p57(KIP2) (KIP2) located at 11p15.5 is predominantly expressed from the maternal allele and encodes a cyclin-dependent kinase inhibitor. We screened a series of 56 HB tumors and five HB cell lines for allelic loss (LOH) of the KIP2 locus by microsatellite analysis and KIP2 coding sequence mutations by single-strand conformation polymorphism analysis. Although LOH at the KIP2 locus occurred in 25% of the cases, no mutations were found. Analysis of KIP2 mRNA expression by competitive reverse transcriptase-polymerase chain reaction revealed up-regulation in nine of 12 HBs compared to matching liver samples. In contrast, mRNA levels of the putative suppressor gene H19 on 11p15.5 were decreased in 10 of 12 tumors, indicating that KIP2 and H19 are not co-regulated in HBs. IGF2 mRNA expression was increased in 11 of 12 HB samples. All HBs showed monoallelic KIP2 expression. However, the overexpression of KIP2 in HBs with maternal loss of 11p15.5 suggests a reactivation of the paternal allele in these cases. Overexpression of KIP2 in HBs argues against a role as a HB suppressor gene.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021841      PMCID: PMC1850179          DOI: 10.1016/S0002-9440(10)64652-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  62 in total

1.  A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes.

Authors:  A Waha; M Watzka; A Koch; T Pietsch; R Przkora; N Peters; O D Wiestler; A von Deimling
Journal:  Brain Pathol       Date:  1998-01       Impact factor: 6.508

2.  Epigenetic lesions at the H19 locus in Wilms' tumour patients.

Authors:  T Moulton; T Crenshaw; Y Hao; J Moosikasuwan; N Lin; F Dembitzer; T Hensle; L Weiss; L McMorrow; T Loew; W Kraus; W Gerald; B Tycko
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

3.  Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour.

Authors:  M J Steenman; S Rainier; C J Dobry; P Grundy; I L Horon; A P Feinberg
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

Review 4.  Genomic imprinting: mechanism and role in human pathology.

Authors:  B Tycko
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

5.  Loss of maternal alleles on chromosome arm 11p in hepatoblastoma.

Authors:  S Albrecht; D von Schweinitz; A Waha; J A Kraus; A von Deimling; T Pietsch
Journal:  Cancer Res       Date:  1994-10-01       Impact factor: 12.701

6.  Absence of WAF1 mutations in a variety of human malignancies.

Authors:  M Shiohara; W S el-Deiry; M Wada; T Nakamaki; S Takeuchi; R Yang; D L Chen; B Vogelstein; H P Koeffler
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

7.  Loss of imprinting in hepatoblastoma.

Authors:  S Rainier; C J Dobry; A P Feinberg
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

8.  Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor.

Authors:  T Taniguchi; M J Sullivan; O Ogawa; A E Reeve
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

9.  Disruption of imprinting caused by deletion of the H19 gene region in mice.

Authors:  P A Leighton; R S Ingram; J Eggenschwiler; A Efstratiadis; S M Tilghman
Journal:  Nature       Date:  1995-05-04       Impact factor: 49.962

10.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.

Authors:  M V Ponce-Castañeda; M H Lee; E Latres; K Polyak; L Lacombe; K Montgomery; S Mathew; K Krauter; J Sheinfeld; J Massague
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

View more
  5 in total

1.  Low and maternal-specific expression of p57KIP2 in hydatidiform mole and its clinical implication.

Authors:  Yali Xiong; Yang Cao; Hongfa Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

Review 2.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

3.  IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors.

Authors:  Ivonne Regel; Melanie Eichenmüller; Saskia Joppien; Johanna Liebl; Beate Häberle; Josef Müller-Höcker; Angelika Vollmar; Dietrich von Schweinitz; Roland Kappler
Journal:  Mol Cancer       Date:  2012-03-08       Impact factor: 27.401

4.  Molecular networks of hepatoblastoma predisposition and oncogenesis in Beckwith-Wiedemann syndrome.

Authors:  Natali S Sobel Naveh; Emily M Traxler; Kelly A Duffy; Jennifer M Kalish
Journal:  Hepatol Commun       Date:  2022-05-04

5.  Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma.

Authors:  S Honda; Y Arai; M Haruta; F Sasaki; M Ohira; H Yamaoka; H Horie; A Nakagawara; E Hiyama; S Todo; Y Kaneko
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.